Key Drivers
- Margin Expansion
- Strong Cash Flow
- Improved Liquidity
AIAI Summary
OMCL is now an execution-dependent earnings-inflection story: strong margin and cash-flow recovery can drive meaningful upside if Titan XT/OmniSphere refresh demand converts into recurring bookings, but investors should wait for consistent large-deal conversion and guidance delivery given limited tolerance for timing-related misses.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Strong Cash Flow
- •Improved Liquidity
OMCL's latest quarter shows sharply improved profitability, cash flow, and liquidity, but high intangibles and still-demanding valuation warrant caution on sustainability.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Negative momentum
OMCL remains in a last-month downtrend below its average, with $32.20–$32.30 support at risk unless it reclaims $33.50–$33.90 resistance.
9.2% decline over the last month
Sentiment & News
Key News Insights:
- •Value Stock
- •Insider Selling
- •DSCSA Integration
Omnicell's value-stock visibility and DSCSA integration support its outlook, though insider selling warrants monitoring.
The compliance technology partnership could strengthen Omnicell's hospital pharmacy offering despite modest insider-sale caution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings